P1047 (10163): Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] L1 Virus-Like Particle [VLP] Vaccine (Gardasil®) in HIV-Infected Children > 7 to < 12 Years of Age

Study Status Study Restriction

Concluded

Not Applicable

Sites where the study was implemented:

CRS ID Site Name City Country

5011

Boston Medical Center Pediatric HIV Program

Boston

United States of America

5083

Rush University Cook County Hospital Chicago NICHD CRS

Chicago

United States of America

Study contacts:

CTS: IMPAACT Operations Center

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.